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Introduction
For many patients with acute leukemia, allogeneic 
hematopoietic stem cell transplantation (HSCT) 
has provided the best chance for long-term 
survival.1-3 Anti-tumour activity of conventional 
(myeloablative) allogeneic HSCT has relied on 
both the administration of high-dose chemo/
radiotherapy given within the conditioning 
regimen, and on the eradication of residual 
leukemic cells by graft-versus-leukemia effects.4 
The power of graft-versus-leukemia effects has been 
best demonstrated by the observation that acute 
myeloid leukemia (AML) patients given grafts from 
identical twins after myeloablative conditioning 
had a 2.5-fold higher risk of relapse than those 
given grafts from human leukocyte antigen (HLA)-
identical siblings.4 The main complications of 
myeloablative allogeneic HSCT include toxicity of 
the conditioning regimen, infections, and graft-
versus-host disease (GVHD; a life-threatening 
disease due to the destruction of host healthy 
organs by donor immune cells).
Autologous HCST has been developed as a way to 
administer high-dose chemoradiotherapy in young 
leukemic patients lacking a human leukocyte 
antigen (HLA)-matched donor. Limitations of this 
approach include the possible contamination of 
the autologous grafts by residual leukemic (stem) 
cells, and the absence of graft-versus-leukemia 
effects. More recently, allogeneic HSCT following 
reduced-intensity conditioning (RIC) or truly non-
myeloablative conditioning has been developed 
as a way to perform allogeneic HSCT in patients 
who are too old or too sick to tolerate high-dose 
chemoradiotherapy.5 In these approaches, the 
burden for tumour eradication depends mainly 
(RIC) or nearly exclusively (non-myeloablative 
conditioning) on graft-versus-leukemia effects 
(Table 1, page 119).6,7 This review discusses the 
current indications for autologous and allogeneic 
HSCT in adult patients with AML or acute 
lymphoblastic leukemia (ALL).
Hematopoietic stem cell transplanta-
tion as treatment for acute myeloid 
leukemia 
AML in first complete remission
Younger patients (<55 years of age)
The indications for allogeneic HSCT have been 
defined most clearly for younger patients with HLA-
identical related donors. Prospective (genetically 
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randomized) studies have demonstrated a 
survival advantage for allogeneic HSCT over 
chemotherapy for patients <55 years of age with 
high risk cytogenetics (defined as any cytogenetic 
abnormality excepted -Y, -X, t(8;21) or inv(16)), 
and intermediate-risk cytogenetics (defined as 
normal cytogenetics or –Y, -X).1,3 This advantage 
was mainly seen in patients younger than 40 
years of age. In contrast, there was no advantage 
(but no disadvantage either) for allogeneic HSCT 
in patients with good-risk cytogenetics (core 
binding factor leukemia; t(8;21) or inv(16)), while 
patients with promyelocytic (t(15;17)) leukemia 
are generally not transplanted in first complete 
remission (CR).
More recently, 2 molecular abnormalities 
have allowed separating patients with normal 
cytogenetics into a high-risk molecular group 
(FLT3 internal tandem duplication (FLT3-ITD) or 
wild type NPM1 and CEBPA) that benefits from 
allogeneic HSCT, and a low-risk molecular group 
(mutated NPM1 without FLT3-ITD or mutated 
CEBPA without FLT3-ITD) that does not benefit 
from allogeneic HSCT.8 Furthermore, patients with 
t(8;21) and c-KIT mutation or FLT3-ITD are also 
reclassified into the high-risk molecular group.
Most groups also recommend performing allogeneic 
HSCT in CR1 in patients who required 2 induction 
courses to achieve a CR, in those with secondary 
AML, and in those with evidence of molecular 
disease (such as persistent WT1 expression) after 
consolidation chemotherapy.9,10 Patients >40 years 
of age with medical comorbidities might benefit from 
a RIC/non-myeloablative conditioning instead of a 
myeloablative conditioning, as recently suggested 
by Sorror et al.11 
With recent progress in HLA typing, the results of 
allogeneic HSCT with 10/10 HLA-allele-matched 
unrelated donors are now approaching those 
observed with HLA-identical sibling donors.12 
Although there is thus far insufficient evidence 
to routinely recommend allogeneic HSCT with 
unrelated donors in patients in first CR, several 
investigators advocate that the indication of 
allogeneic HSCT with HLA-identical sibling or 
HLA-matched unrelated donors might be similar 
(Table 2) since the 2 procedures are associated with 
almost similar risks of non-relapse mortality.13 This 
is particularly accepted for patients in the high-risk 
group.
The role of autologous HSCT in AML patients in 
CR1 remains debated. Since the relapse incidence 
after autologous HSCT in patients with high-risk 
cytogenetics is very high, this treatment option 
is being abandoned in this group of patients.1 In 
contrast, large meta-analyses are ongoing to define 
the role of autologous HSCT, if any, in patients with 
good-risk cytogenetics or good-risk molecular AML. 
Currently, the results of autologous HSCT, and of 
3-4 courses of high-dose cytarabine consolidation 
are considered equivalent in term of overall survival, 
and the choice may rely on patient preference. 
Autologous HSCT with peripheral blood stem 
cells should always be performed after ≥2 courses 
of consolidation chemotherapy, and should not be 
performed with peripheral blood stem cells (PBSC) 
containing >7.5x106 CD34/kg.14
Older patients (>55-60 years of age)
Early results with allogeneic HSCT after non-
myeloablative conditioning and RIC for patients 
with AML in CR1 are encouraging, with 2-year 
survival rates ranging from 48-79% among studies.5 
Furthermore, several retrospective studies have 
demonstrated similar outcomes in adult patients 
with AML in CR given either myeloablative or non-
Table 1. Anti-tumour mechanisms of allogeneic and autologous hematopoietic stem cell trans-
plantation (HSCT).
High-dose chemo/radiotherapy Graft-versus-leukemia effects
Myeloablative allogeneic HSCT ++++ ++++
Reduced-intensity allogeneic HSCT ++ ++++
Non-myeloablative allogeneic HSCT +/- ++++
Autologous (or syngeneic) HSCT ++++ -
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myeloablative conditioning.15,16 Based on these 
results, several investigators advocate performing 
RIC or non-myeloablative HSCT in patients with 
high-risk AML (as defined above) in first CR, at 
least in patients without significant comorbidities. 
A prospective randomized trial comparing RIC 
transplantation versus no transplantation is 
ongoing in Europe in order to better define the 




Patients with refractory AML are defined as those 
who never achieve a CR, as well as patients who 
experience leukemia relapse within 6 months of 
diagnosis. Those patients have a poor prognosis 
with chemotherapy, but also with allogeneic HSCT. 
Indeed, for patients with primary refractory AML, 
conventional myeloablative HSCT results in about 
10% long-term survival. However, recent strategies 
combining intensive rescue chemotherapy with 
reduced-intensity conditioning allogeneic HSCT 
(sequential regimens) are encouraging. For 
example, a 40% survival rate at 2 years has been 
achieved in patients with refractory/relapsed AML 
with the FLAMSA-RIC-ATG regimen combining 
fludarabine 30 mg/m2, high-dose cytarabine 
2 g/m2, and amsacrin 100 mg/m2 from days -12 
to -9, 4 Gy total body irradiation (TBI) on day -5, 
cyclophosphamide (40 mg/kg with HLA-identical 
sibling, 60 mg/kg with unrelated or mismatched 
donors) on days -4 and -3, and rabbit antithymocyte 
globulin (10 mg/kg for HLA-identical sibling, 20 
m/kg for unrelated or mismatched donors) from 
days -4 to day -2.17
Relapsed AML
Even though prolonged second remissions can 
be achieved with chemotherapy in some patients 
with relapsed AML associated with inv(16) or with 
relapsed promyelocytic leukemia, no chemotherapy 
regimen has offered durable second remissions or 
long-term survivals. This is in sharp contrast with 
results reported by the Center for International 
Blood and Marrow Transplant Research (CIBMTR), 
where patients with AML in second CR had 
5-year probabilities of survival of about 35% after 
allogeneic HSCT, and about 25% after autologous 
HSCT.18 An open question is whether patients with 
AML in first untreated relapse should go directly 
to transplant or should first be re-induced with 
conventional chemotherapy.19 At least in patients 
with only cytogenetic or molecular relapse, 
allogeneic HSCT without re-induction appears as 
a good option.
Table 2. Classification of acute myeloid leukemia (AML) according to genetic and molecular 
factors.
Factor
Low-risk AML - inv(16) or t(16;16)
- t(8;21) without c-KIT mutation and with <20,000 WBC 
- t(15;17)
- normal cytogenetics with mutated CEBPA but without FLT3-ITD
- normal cytogenetics with mutated NPM1 but without FLT3-ITD
Intermediate-risk AML - normal cytogenetics with wild type NPM1 and CEBPA, and without FLT3-ITD
- -X, -Y, +6, del(12p)
- t(8;21) without c-KIT mutation but with ≥20,000 WBC
High-risk AML - abnormal cytogenetics not belonging to the low-risk or standard-risk groups
- t(8;21) with c-KIT mutation
- normal cytogenetics (or –Y?) with FLT3-ITD
- secondary AML (after MDS or chemotherapy)
- 2 courses of induction needed to achieve CR
- minimal residual disease after consolidation chemotherapy
WBC=white blood cells, ITD=internal tandem duplication, MDS=myelodysplastic syndrome, CR=complete remission.
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Hematopoietic stem cell transplanta-
tion as treatment for acute lympho-
blastic leukemia 
ALL in first complete remission
Given the accumulating new data regarding risk 
stratification of adult ALL on the one hand, and 
the development of RIC regimens on the other 
hand, the indications for allogeneic HSCT in ALL 
in CR1 are a moving target. Historically, poor-risk 
factors for ALL included age >35 years, elevated 
white blood cells (WBC) at diagnosis (defined 
as >100x109/l for B-cell ALL and >30x109/l for 
T-cell ALL), T-cell lineage versus B-cell lineage, 
presence of adverse cytogenetics (Philadelphia 
chromosome (Ph; t(9;22)), t(4;11)), slow response 
to induction, and mature B-cell phenotype.20 Recent 
studies have improved the cytogenetic classification 
of ALL. Patients with t(9;22), t(4;11), t(8;14), 
complex caryotype (defined as ≥5 chromosomal 
abnormalities), or low hypodiploidy/near triploidy 
were shown to have the worse survival, while 
patients with high hyperdiploidy or a del(9p) had 
a favorable survival.21 Furthermore, the presence of 
a NOTCH1/FBXW7 mutation was associated with 
favorable outcome in patients with T-cell ALL.
Ph+ ALL patients have a very poor outcome with 
chemotherapy, and allogeneic HSCT with a HLA-
identical donor or an alternative donor should be 
proposed to all eligible patients. In 2005, Yanada et 
al. reported the results of a meta-analysis of 1,274 
patients with ALL in first CR included in either 
one of 7 prospective studies reported between 
1994 and 2005.22 Results of the meta-analysis 
demonstrated a survival benefit for patients with 
a donor that was significant in high-risk ALL 
patients. Goldstone et al. reported the results of 
the largest ALL trial to date in which all patients 
with a sibling donor were referred to allogeneic 
HSCT in first CR, whereas those without a donor 
were randomized between chemotherapy or 
autologous HSCT.23 The 5-year survival rate was 
53% in patients with a donor versus 45% in patients 
without donor (p=0.01). Interestingly, high-risk 
patients (defined as patients older than 35 years 
or those with a high WBC count at presentation 
(≥30x109/l for T-cell lineage and ≥100x109/l for 
B-cell lineage)) along with all Ph+ patients had 
a survival of 41% versus 35% for donor versus no 
donor, respectively, which was not significantly 
different (p=0.2). However, 5-year survival was 
significantly improved among patients at standard 
risk (62% versus 52% for donor versus no donor, 
respectively (p=0.02)). High-risk patients had 
significantly lower risk of relapse in the donor 
group (p<0.0001), but this was offset by a higher 
risk of transplant-related mortality, perhaps 
because age >35 years was one of the factors 
classifying patients in the high-risk group. Patients 
without a donor randomized to autologous HSCT 
had worse 5-year survival than those randomized 
to receive additional chemotherapy (37% versus 
45%, p=0.03), but the survival advantage for the 
donor arm persisted when patients randomized 
to the autologous HSCT arm were censored at the 
time of autologous HSCT. 
For patients without a HLA-identical sibling, a 
recent analysis by the CIBMTR observed similar 
outcomes in ALL patients transplanted from a 8/8 
Key messages for clinical practice
1. Patients <55 years of age with high-risk acute myeloid leukemia (AML; as defined in 
Table 2) might benefit from an allogeneic hematopoietic stem cell transplantation 
(HSCT) with a human leukocyte antigen (HLA)-matched related or unrelated donor.
2. Patients <55 years of age with high-risk acute lymphoblastic leukemia (ALL) 
benefit from an allogeneic HSCT with a HLA-matched related or unrelated donor. 
3. Older patients with high-risk AML or ALL might benefit from reduced-intensity 
allogeneic HSCT.
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HLA-allele-matched unrelated donor than in those 
transplanted from a HLA-identical sibling donor.24 
Furthermore, Mohty et al. recently reported 
encouraging results for ALL patients given RIC 
allogeneic HSCT in first CR in European Group 
for Blood and Marrow transplantation (EBMT)-
affiliated centers, with a 2-year overall survival rate 
of 52%.25 This suggests that RIC allogeneic HSCT 
might be a reasonable option for older patients 
with ALL in first CR.
Advanced ALL
The outcome in patients with relapsed ALL is 
poor, and in many cases salvage after relapse is not 
feasible.26 Nevertheless, adult patients who can 
achieve a second CR might benefit from allogeneic 
HSCT with a 5-year survival of about 25%.18 
Furthermore, survival for infants with ALL in CR2 
offered an allogeneic HSCT is more encouraging.
Conclusions
Recent analyses based on cytogenetics, molecular 
markers and status of minimal residual disease have 
helped to better stratify patients among those who 
might benefit from allogeneic HSCT and those who 
might not.
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